Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsored by: |
ZIOPHARM |
---|---|
Information provided by: | ZIOPHARM |
ClinicalTrials.gov Identifier: | NCT00591136 |
Dose-finding and pharmacokinetic trial of orally administered Indibulin to patients with solid tumors.
Condition | Intervention | Phase |
---|---|---|
Solid Tumors |
Drug: indibulin |
Phase I |
Study Type: | Interventional |
Study Design: | Treatment, Non-Randomized, Open Label, Uncontrolled, Single Group Assignment, Safety Study |
Official Title: | Dose-Finding and Pharmacokinetic Trial of Orally Administered D-24851 to Patients With Solid Tumors |
Estimated Enrollment: | 40 |
Study Start Date: | April 2003 |
Estimated Study Completion Date: | March 2009 |
Estimated Primary Completion Date: | March 2009 (Final data collection date for primary outcome measure) |
Arms | Assigned Interventions |
---|---|
Single Arm: Experimental |
Drug: indibulin
Dose escalation, daily dosing for 14 days every 3 weeks, for up to 4 months
|
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria
Exclusion Criteria
Responsible Party: | ZIOPHARM Oncology, Inc ( Brian Schwartz, Chief Medical Officer ) |
Study ID Numbers: | IBL1001 |
Study First Received: | December 26, 2007 |
Last Updated: | December 26, 2007 |
ClinicalTrials.gov Identifier: | NCT00591136 |
Health Authority: | United States: Food and Drug Administration; Netherlands: Dutch Health Care Inspectorate |
Signs and Symptoms |